

February 14, 2024

Press Release

TOWA PHARMACEUTICAL CO., LTD.

Notice of Acquisition of Approval for Application for Partial Change of Manufacturing and Marketing Approval for Esomeprazole Capsules concerning the Addition of a Manufacturing Plant

TOWA PHARMACEUTICAL CO., LTD. (Headquarters: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida; hereinafter, the “Company”) announces the acquisition, effective today, February 14, 2024., of approval for application for partial change of manufacturing and marketing approval for Esomeprazole Capsules 10 mg/20 mg “Towa” concerning the addition of a manufacturing plant of the product.

The approval pertains to the addition, as a manufacturing plant of the product, of the Martorelles Plant, which is operated in Spain by Towa Pharmaceutical Europe, S.L., a group company of the Company’s consolidated subsidiary Towa Pharma International Holdings, S.L (hereinafter, Towa INT). The Martorelles Plant is a production base that conforms to the standards of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), and the Company has received new certification for its manufacturing of a drug for distribution in Japan.

Leveraging its strength of efficient mass production using large granulating machines, the Martorelles Plant has been supplying products to the U.S. and European markets. By manufacturing a product for distribution in Japan under the newly granted approval, the Martorelles Plant will not only strengthen the Group’s production backup system but also contribute to the resolution of the current issue of stable supply in Japan.

This is one of the Company’s achievements from its efforts to realize group synergy after the acquisition of Towa INT, and the Company will work to further strengthen its business going forward through, for example, joint development that effectively utilizes technologies of each group company.



Towa Pharmaceutical Europe, S.L. Martorelles Plant

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Fax: +81-6-7177-4960 / Email: kouhou@towayakuhin.co.jp